Loading
NASDAQHealthcareBiotechnology
Latest quote
$1.25
+$0.07 · +5.93%
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Previous close
$1.25
+$0.07 · +5.93%
Regular session · ET · Market data may be delayed.
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Day range
Current $1.25
52-week range
Current $1.25
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
32
Expensive
Sentiment
38
Bearish
Risk
48
Elevated Risk
Momentum
64
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Day range
Current $1.25
52-week range
Current $1.25
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 77M USD | 116.37M USD | 141.8M USD | 98.4M USD | 60.17M USD |
| Selling, general, and administrative | 23.85M USD | 26.09M USD | 28.48M USD | 29.04M USD | 23.39M USD |
| Operating expenses | 104.02M USD | 142.47M USD | 170.28M USD | 127.44M USD | 83.56M USD |
| Interest income | 3.96M USD | 9.37M USD | 10.65M USD | 4.28M USD | 91 USD |
| Interest expense | 1.6M USD | 1.73M USD | 1.57M USD | 238K USD | 13K USD |
| Depreciation and amortization | 706K USD | 872K USD | 836K USD | 342K USD | 51K USD |
| Operating income | −104.02M USD | −142.47M USD | −170.28M USD | −127.44M USD | −83.56M USD |
| Net income | −101.7M USD | −134.85M USD | −160.81M USD | −123.48M USD | −83.46M USD |
Company facts updated Oct 11, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI7.03M0.00%2.3T USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM3.13M0.00%78.74B USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF2.37M0.00%95.4B USD0.05%$235+0.80%
Vanguard Russell 2000 ETFVTWO1.2M0.01%18B USD0.06%$112.66+0.50%
iShares Russell 2000 Growth ETFIWO1.08M0.01%13.92B USD0.24%$356.78+0.94%
iShares Micro-Cap ETFIWC362.12K0.03%1.32B USD0.60%$183+0.11%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM260K0.22%116.88M USD0.73%$15.9402+0.25%
Vanguard Russell 2000 Growth ETFVTWG226.09K0.01%1.7B USD0.06%$260.49+0.91%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMVanguard Russell 2000 Growth ETFVTWGAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
